|本期目录/Table of Contents|

[1]赵立明综述,胡永成审校.骨巨细胞瘤多学科联合的诊治进展[J].天津医科大学学报,2016,22(01):90-封3.
点击复制

骨巨细胞瘤多学科联合的诊治进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
22卷
期数:
2016年01期
页码:
90-封3
栏目:
综述
出版日期:
2016-01-20

文章信息/Info

Title:
-
文章编号:
1006-8147（2016）01-0090-04
作者:
赵立明1综述; 胡永成2审校
(1.天津医科大学研究生院，天津，300070；2.天津市天津医院脊柱二科，天津 300211)

Author(s):
-
关键词:
骨巨细胞瘤; 组织病理学; RANKL; 狄诺塞麦
Keywords:
-
分类号:
R738.1
DOI:
-
文献标志码:
A
摘要:
-
Abstract:
-

参考文献/References:

[1] 赵立明, 徐明, 胡永成, 等. 376例膝关节周围骨巨细胞瘤的临床特征分析[J]. 中华骨科杂志, 2015,35(2):97

[2] Niu X, Zhang Q, Hao L, et al. Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution[J]. J Bone Joint Surg Am, 2012,94(5):461

[3] Campanacci M, Baldini N, Boriani S, et al. Giant-cell tumor of bone[J]. J Bone Joint Surg Am, 1987,69(1):106

[4] van der Heijden L, Dijkstra P D, van de Sande M A, et al. The clinical approach toward giant cell tumor of bone[J]. OncoloGist, 2014,19(5):550

[5] Yanagisawa M, Okada K, Tajino T, et al. A clinicopathological study of giant cell tumor of small bones[J]. Ups J Med Sci, 2011,116(4):265

[6] 袁斌斌, 胡永成, 王臻, 等. 膝关节周围骨巨细胞瘤病理性骨折影像学特征研究[J]. 中华骨科杂志, 2014,34(5):564

[7] Klenke F M, Wenger D E, Inwards C Y, et al. Giant cell tumor of bone: risk factors for recurrence[J]. Clin Orthop Relat Res, 2011,469(2):591

[8] Hemingway F, Taylor R, Knowles H J, et al. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II[J]. Bone, 2011,48(4):938

[9] Hemingway F, Kashima T G, Mahendra G, et al. Smooth muscle actin expression in primary bone tumours[J]. Virchows Arch, 2012,460(5):525

[10] Jaffe H L. Hyperparathyroidism[J]. Bull N Y Acad Med, 1940,16(5):291

[11] Clohisy D R, Vorlicky L, Oegema T J, et al. Histochemical and immunohistochemical characterization of cells constituting the giant cell tumor of bone[J]. Clin Orthop Relat Res, 1993(287):259

[12] Balla P, Moskovszky L, Sapi Z, et al. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone[J]. Histopathology, 2011,59(3):376

[13] Thomas D M. RANKL, denosumab, and giant cell tumor of bone[J]. Curr Opin Oncol, 2012,24(4):397

[14] Gorunova L, Vult V S F, Storlazzi C T, et al. Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations[J]. Genes Chromosomes Cancer, 2009,48(7):583

[15] Forsyth R G, De Boeck G, Bekaert S, et al. Telomere biology in giant cell tumour of bone[J]. J Pathol, 2008,214(5):555

[16] Saito T, Mitomi H, Suehara Y, et al. A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up[J]. Pathol Res Pract, 2011,207(10):664

[17] Cowan R W, Singh G. Giant cell tumor of bone: a basic science perspective[J]. Bone, 2013,52(1):238

[18] Dahlin D C, Cupps R E, Johnson E J. Giant-cell tumor: a study of 195 cases[J]. Cancer, 1970,25(5):1061

[19] Enneking W F, Spanier S S, Goodman M A. A system for the surgical staging of musculoskeletal sarcoma[J]. Clin Orthop Relat Res, 1980(153):106

[20] Antal I, Sapi Z, Szendroi M. The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone[J]. Int Orthop, 1999,23(6):315

[21] Cheng J C, Johnston J O. Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases[J]. Clin Orthop Relat Res, 1997(338):205

[22] 胡永成, 陈雁西, 伦登兴. 骨巨细胞瘤临床评分系统的建立及临床验证[J]. 中华骨科杂志, 2011,31(2):105

[23] Craig H I. Bisphosphonates: game changers[J]. Oncology (Williston Park), 2015,29(1):16

[24] 高旭东. 少见部位骨巨细胞瘤的影像学诊断[J]. 当代医学, 2013(25):32

[25] 孙伟杰, 苏永彬, 王玲, 等. 增强扫描CT值在骨巨细胞瘤诊断中的价值[J]. 中华放射学杂志, 2013,47(5):444

[26] 韩月东, 张学昕, 徐朝霞. 骨巨细胞瘤的MRI表现与病理基础研究[J]. 实用放射学杂志, 2002,18(8):699

[27] van der Heijden L, Dijkstra P D, Campanacci D A, et al. Giant cell tumor with pathologic fracture: should we curette or resect?[J]. Clin Orthop Relat Res, 2013,471(3):820

[28] 王晗, 胡永成, 于秀淳, 等. 膝关节周围骨巨细胞瘤治疗的多中心回顾性研究[J]. 中华骨科杂志, 2012,32(11):1040

[29] Klenke F M, Wenger D E, Inwards C Y, et al. Giant cell tumor of bone: risk factors for recurrence[J]. Clin Orthop Relat Res, 2011,469(2):591

[30] Prosser G H, Baloch K G, Tillman R M, et al. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone[J]. Clin Orthop Relat Res, 2005(435):211

[31] Coroneos C J, O’Sullivan B, Ferguson P C, et al. Radiation therapy for infiltrative giant cell tumor of the tendon sheath[J]. J Hand Surg Am, 2012,37(4):775

[32] Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study[J]. Lancet Oncol, 2010,11(3):275

[33] Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study[J]. Lancet Oncol, 2013,14(9):901

[34] Aponte-Tinao L A, Piuzzi N S, Roitman P, et al. A High-grade sarcoma arising in a patient with recurrent benign Giant cell tumor of the proximal tibia while receiving treatment with denosumab[J]. Clin Orthop Relat Res, 2015,473(9):3050

相似文献/References:

[1]张 俊,孟令贺,单士军,等. 康复新液对实验性大鼠皮肤切割伤痂下愈合的影响[J].天津医科大学学报,2014,20(03):192.
　ZHANG Jun,MENG Ling-he,SHAN Shi-jun,et al.Effect of Kangfuxin liquid on subcrustal wound healing of rat[J].Journal of Tianjin Medical University,2014,20(01):192.

备注/Memo

备注/Memo:
作者简介 赵立明（1989-），男，硕士在读，研究方向：骨外科学；E-mail：lemmezhao@hotmail.com。
更新日期/Last Update: 2016-01-26